Effects of Antitumor Necrosis Factor Therapy on Osteoprotegerin, Neopterin, and sRANKL Concentrations in Patients with Rheumatoid Arthritis

Figure 2

Osteoprotegerin concentrations of patients with rheumatoid arthritis according to their adalimumab treatment response: (a) compares OPG levels of patients with consecutive remission (, light grey boxes) to OPG concentrations of patients who did not achieve remission (, dark grey boxes); (b) shows that OPG concentrations decrease significantly in patients with a good EULAR response after 12 weeks of adalimumab therapy (, light grey boxes).

(a)

(b)